Immunotherapy with Bet v 1 derived contiguous overlapping peptides leads to long-term immunoregulatory responses

Détails

ID Serval
serval:BIB_8D6E5680E22A
Type
Actes de conférence (partie): contribution originale à la littérature scientifique, publiée à l'occasion de conférences scientifiques, dans un ouvrage de compte-rendu (proceedings), ou dans l'édition spéciale d'un journal reconnu (conference proceedings).
Sous-type
Abstract (résumé de présentation): article court qui reprend les éléments essentiels présentés à l'occasion d'une conférence scientifique dans un poster ou lors d'une intervention orale.
Collection
Publications
Titre
Immunotherapy with Bet v 1 derived contiguous overlapping peptides leads to long-term immunoregulatory responses
Titre de la conférence
Annual Congress SGAI-SSAI, Advances in immunology and allergology: from research to diagnosis and therapy
Auteur(s)
Spertini F., Barbier N., Thierry A.C., Audran R., Charlon V., Reymond C.
Adresse
Lugano, Switzerland, March 17-18, 2011
ISBN
0344-5062
Statut éditorial
Publié
Date de publication
2011
Peer-reviewed
Oui
Volume
34
Série
Allergologie
Pages
86-87
Langue
anglais
Notes
Publication type : Meeting Abstract
Résumé
Background: Allergen-specific immunotherapy with whole pollen extract may induce anaphylaxis, is poorly standardized and of long duration.We thus designed a randomized, placebo-controlled phase I/II clinical trial in volunteers with birch pollen allergic rhinitis and asthma to evaluate the safety and immunogenicity of a novel immunotherapy based on contiguous overlapping peptides (COPs) derived from Bet v 1, the major birch pollen allergen. Methods: A mixture of three COPs (AllerT™, Anergis SA, Switzerland) spanning the whole Bet v 1 molecule was selected for its inability to bind IgE. Prior to the pollen season, AllerT (in Alum) was injected subcutaneously to 15 adult volunteers at D0 (57 g), D7, D14, D21 and D51 (95 g each). Control volunteers (n = 5) only received the adjuvant. Results: Overall AllerT was safe. No serious adverse events and no immediate allergic reactions were reported. AllerT induced a vigorous early Bet v 1 specific immune response marked by vaccine associated INF- and IL- 10 secretion. This contributed to a strong anti-Bet v 1-specific IgG4 enhancement. Moreover, 2 months after the second season post treatment (July 2010), serum Bet v 1 specific IgG4 response was still markedly increased as compared to pre-treatment values and to placebo whereas post seasonal Bet v 1 specific IgE titers were similar to baseline values. Conclusion: Our data indicate that immunotherapy with a mixture of three COPs derived from Bet v 1 (AllerT) was safe and immunogenic, and led to long-term immunological memory.
Mots-clé
,
Web of science
Création de la notice
07/04/2011 9:33
Dernière modification de la notice
03/03/2018 19:15
Données d'usage